EastGate Biotech Corp. announced that it has restructured its Joint Venture Agreement in Pakistan. The rationale behind the restructuring was to initiate a branding campaign that expanded the purpose of the Joint Venture beyond Insugin. An independent company called EastGate Biotech Pakistan was established by the local partner with the same ownership structure of 51% held by EastGate Biotech and 49% held by EastGate Biotech Pakistan. The objectives and activities of the Joint Venture Agreement include: Register alternative insulin platform products in Pakistan, with the main focus on Insugin, liquid insulin mouth rinse solution. Conduct clinical trials for registration purposes for Insugin. Market and distribute approved Insugin product in Pakistan. Conduct clinical trials for alternative insulin product for the Alzheimer’s indication. Register alternative insulin product for the Alzheimer’s indication. Market and distribute approved alternative insulin product for the Alzheimer’s indication in Pakistan. Assist in the registration of plasma-derived medicines, Human Serum Albumin 20%, 50 ml, 100 ml for which a license is held by the local partner in order to exclusively introduce to the Canadian market. Human Serum Albumin (HSA) is made of plasma proteins from human blood. It is one of the primary components of blood and typically extracted from expired blood. This medicine works by increasing plasma volume or levels of albumin in the blood. HSA is used to replace blood volume loss resulting from trauma or an injury that causes blood loss. The global plasma fractionation market is projected to reach $29.5 Billion by 2023 from $21.23 billion in 2018. Blood Fractionation is a critical, essential, and even a matter of national security to every country that wants to be independent of import and reliance on a single local producer.